Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Quinoline. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.52 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.40 |
| ▸ | FKBP5 | Q13451 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 8/20 | 0.38 |
| ▸ | POLB | P06746 | 3/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 7/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.37 |
| ▸ | CASP1 | P29466 | 1/20 | 0.37 |
| ▸ | CASP7 | P55210 | 1/20 | 0.37 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.37 |
| ▸ | PLK1 | P53350 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.35 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.35 |
| ▸ | RELA | Q04206 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Quinoline SCHEMBL1335063 | 0.92 | ALDH1A1 (0.46) | ALDH1A1PABPC1FKBP5NPC1POLB | |
| Quinoline SCHEMBL2029469 | 0.91 | ALDH1A1 (0.63) | ALDH1A1FKBP5NPC1POLBMEN1 | |
| Quinoline SCHEMBL27685815 | 0.91 | ALDH1A1 (0.63) | ALDH1A1FKBP5NPC1POLBMEN1 | |
| Quinoline SCHEMBL27277627 | 0.91 | ALDH1A1 (0.63) | ALDH1A1FKBP5NPC1POLBMEN1 | |
| Quinoline SCHEMBL27877830 | 0.91 | ALDH1A1 (0.63) | ALDH1A1FKBP5NPC1POLBMEN1 | |
| Quinoline SCHEMBL27268450 | 0.89 | ALDH1A1 (0.61) | ALDH1A1FKBP5NPC1POLBMEN1 | |
| Quinoline SCHEMBL28232319 | 0.89 | ALDH1A1 (0.61) | ALDH1A1PABPC1FKBP5NPC1POLB | |
| Quinoline SCHEMBL28126307 | 0.89 | ALDH1A1 (0.61) | ALDH1A1FKBP5NPC1POLBMEN1 | |
| Quinoline SCHEMBL27929361 | 0.89 | ALDH1A1 (0.61) | ALDH1A1FKBP5NPC1POLBMEN1 | |
| Quinoline SCHEMBL27750058 | 0.89 | ALDH1A1 (0.61) | ALDH1A1FKBP5NPC1POLBMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10882876-B2 | Pegylated imidazoquinolines as TLR7 and TLR8 agonists | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2021-01-05 | — | — | US | disclosed |
| EP-3390417-B1 | PEGYLATED IMIDAZOQUINOLINES AS TLR7 AND TLR8 AGONISTS | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2020-08-26 | — | — | EP | disclosed |
| US-10351582-B2 | Pegylated imidazoquinolines | GLAXOSMITHKLINE BIOLOGICALS, S.A. (BE) | 2019-07-16 | — | — | US | disclosed |
| CN-109576712-A | The carbon dioxide corrosion inhibitor and preparation method thereof of modified graphene oxide preparation | 华中科技大学 | 2019-04-05 | — | — | CN | disclosed |
| US-20180362560-A1 | PEGYLATED IMIDAZOQUINOLINES | GLAXOSMITHKLINE BIOLOGICALS, SA (BE) | 2018-12-20 | — | — | US | disclosed |
| EP-3390417-A1 | PEGYLATED IMIDAZOQUINOLINES AS TLR7 AND TLR8 AGONISTS | GlaxoSmithKline Biologicals S.A. (BE) | 2018-10-24 | — | — | EP | disclosed |
| CN-106478510-B | Alkynol base imidazolinium compounds, the corrosion inhibiter for carbon dioxide drive and preparation | 武汉楚博士科技有限公司 | 2018-01-30 | — | — | CN | disclosed |
| EP-2341933-B1 | LIPIDATED IMIDAZOQUINOLINE DERIVATIVES | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2017-11-22 | — | — | EP | disclosed |
| WO-2017102652-A1 | PEGYLATED IMIDAZOQUINOLINES AS TLR7 AND TLR8 AGONISTS | GLAXOSMITHKLINE BIOLOGICALS S.A. (BE) | 2017-06-22 | — | — | WO | disclosed |
| CN-106478510-A | Alkynol base imidazolinium compounds, the corrosion inhibiter for carbon dioxide drive and preparation | 武汉楚博士科技有限公司 | 2017-03-08 | — | — | CN | disclosed |
| US-8946421-B2 | Lipidated imidazoquinoline derivatives | GLAXOSMITHKLINE BIOLOGICALS S.A. (BE) | 2015-02-03 | — | — | US | disclosed |
| US-20140323731-A1 | LIPIDATED IMIDAZOQUINOLINE DERIVATIVES | GLAXOSMITHKLINE BIOLOGICALS S.A. (BE) | 2014-10-30 | — | — | US | disclosed |
| US-8624029-B2 | Lipidated imidazoquinoline derivatives | GLAXOSMITHKLINE BIOLOGICALS S.A. (BE) | 2014-01-07 | — | — | US | disclosed |
| US-20110282061-A1 | Lipidated Imidazoquinoline Derivatives | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2011-11-17 | — | — | US | disclosed |
| EP-2341933-A1 | LIPIDATED IMIDAZOQUINOLINE DERIVATIVES | GlaxoSmithKline Biologicals SA (BE) | 2011-07-13 | — | — | EP | disclosed |
| WO-2010048520-A1 | LIPIDATED IMIDAZOQUINOLINE DERIVATIVES | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2010-04-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180362560-A1 | PEGYLATED IMIDAZOQUINOLINES | TLR7, TLR8, TLR1 | ALDH1A1 2063/4885PABPC1 4071/4885FKBP5 3671/4885 |
| US-10351582-B2 | Pegylated imidazoquinolines | TLR7, TLR8, TLR1 | ALDH1A1 2063/4885PABPC1 4071/4885FKBP5 3671/4885 |
| US-20140323731-A1 | LIPIDATED IMIDAZOQUINOLINE DERIVATIVES | IFNG, IRF3, IFNAR1 | ALDH1A1 3213/4885PABPC1 4669/4885FKBP5 2993/4885 |
| US-20110282061-A1 | Lipidated Imidazoquinoline Derivatives | IFNG, IRF3, IFNAR1 | ALDH1A1 3201/4885PABPC1 4671/4885FKBP5 2990/4885 |
| US-10882876-B2 | Pegylated imidazoquinolines as TLR7 and TLR8 agonists | TLR7, TLR8, TLR3 | ALDH1A1 3517/4885PABPC1 3859/4885FKBP5 4021/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.